All News
RETRO - Taper or Not: You Decide
A prospective, phase 3 trial of rheumatoid arthritis (RA) patients in sustained remission has shown more than half will flare if disease-modifying antirheumatic drugs (DMARD) therapy is tapered or discontinued and that remission is best maintained by continued DMARD therapy.
Read Article
Excited to share that the 2nd ed. Musculoskeletal Ultrasound in Rheumatology Review is the #1 new release in ultrasonography books on @amazon #ultrasound #RheumTwitter #meded #MedTwitter #POCUS #FOAMed https://t.co/b0ptm3MKid
Minna Kohler, MD, RhMSUS minnakohlermd ( View Tweet)
Upadacitinib was shown to be effective in two Phase 3 SELECT-AXIS trials. 1st trial: in bDMARD-IR AS pts the ASDAS resp was 44% vs 10% PBO at wk 14). 2nd trial: in nr-axSpA, the ASDAS response at wk 14: 42% vs 18% PBO. https://t.co/rnv9VVITeE
Links:
Dr. John Cush RheumNow ( View Tweet)
Deucravacitinib (oral TYK2 inhibitor) in development, has been shown to be highly effective in psoriasis & PsA, but failed to meet its primary endpoints at wk 12 (remission) in Ulcerative Colitis in the phase 2 LATTICE-UC trial vs placebo https://t.co/ZGYuozFgOk
Links:
Dr. John Cush RheumNow ( View Tweet)
Check out the most recent podcast where we “Ask Cush Anything” and discuss a dozen news items from the last week.
https://t.co/Xb81eWEZ1q
#RheumNow
Links:
Dr. John Cush RheumNow ( View Tweet)
Clinical Associations with Myositis Antibodies
Read the full post on #RheumNow
https://t.co/tzPU1scc8x https://t.co/F537tPAQTU
Links:
Dr. John Cush RheumNow ( View Tweet)
WHO's Strategic Advisory Group on immunisation has advised an addition COVID vaccination in those >60 years and the immunosuppressed (due to a higher risk of breakthrough infections) https://t.co/NcGr8EMDaO
Links:
Dr. John Cush RheumNow ( View Tweet)
The CDC estimates of the national prevalence of arthritis and arthritis-attributable activity limitations (AAAL) show a continued increase in absolute number: 58.5 million US adults have arthritis, 25.7 million of whom have AAAL.
Read more on #RheumNow
https://t.co/9RNIduVCZh https://t.co/fzxWMbcEfU
Links:
Dr. John Cush RheumNow ( View Tweet)
Most common reasons for starting canakinumab? Survey of 58 MDs (caring for 147 febrile pts) 1) perceived efficacy(81%), 2) lack of prior response (41%), 3) good safety (40%). Efficacy w/ HIDS/MKD (91%), no response w/ FMF (52%) https://t.co/JjxaUyBnyB
Links:
Dr. John Cush RheumNow ( View Tweet)
Clinical Associations with Myositis Antibodies
Read the full article on #RheumNow
https://t.co/tzPU1scc8x https://t.co/xxF1gIulwY
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Several studies have suggested that biologic Rx of Psoriasis may lower risk of later PsA. New study of nearly 2 million PSO (15k given biologic, 20K given oral Rx). The risk developing PsA higher w/ biologic (aHR 4.48) vs oral or phototherapy https://t.co/Na5EfWelkY https://t.co/0sL18UWjhO
Links:
Dr. John Cush RheumNow ( View Tweet)
We are reviewing cases from Ask Cush Anything and almost a dozen news items and reports on this week’s podcast. Download today.
https://t.co/Xb81eWEZ1q https://t.co/K6zPKtwAD7
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: An erosive hand osteoarthritis (EOA) study from the Osteoarthritis Initiative shows that EOA is more common in older women and is strongly linked to further progressive, articular structural damage.
https://t.co/XOVKNj423l
#RheumNow https://t.co/CYxW6mJpCH
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
Upadacitinib RA program (5306 pts) the risk of H. zoster by Rx and dose (HZ/100PYs)
MTX = 0.8/100PY
ADA+MTX= 1.1/100PY
UPA 15 mg= 3.0/100PY
UPA 30 mg = 5.3/100PY
Hence there is a 4-5X risk of HZ w/ JAKinhibitors
https://t.co/wo9ih5PJ77
#RheumNow https://t.co/h1GoGzADdv
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
“Hiker’s feet” newly proposed cutaneous foot manifestations of dermatomyositis. Most pts had the antisynthetase syndrome (with anti-Jo-1) and almost all had mechanic’s hands. Such findings should prompt a search for ILD https://t.co/98EAQUHJbz https://t.co/Cw6rSIUyW2
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
The AAOS has published their Clinical Practice Guideline for Management of Osteoarthritis of the Knee (Non-Arthroplasty); updating 19 of 29 evidence-based recommendations and focuses on nonsurgical treatmentss to provide pain and patient function.
https://t.co/faLi0WQt8F https://t.co/PI7jYN1VB9
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
Secukinumab (IL-17 inhibitors) can be safely used in HIV spondyloarthritis patients. https://t.co/hpCRJkR9w7 https://t.co/qwbrvGkriX
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
ASBMR meeting presented results of the ASTEROID trial in osteogenesis imperfecta; Setrusumab, investigational Mab inhibitor of sclerostin, failed to improve radial trabecular BMD (primary endpt), but did improve lumbar/hip/femoral BMD https://t.co/xSDIiffjb7 https://t.co/H4Cl8rH3Bq
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR 2021 is just a few weeks away - are you ready? I'll review cases and questions submitted by viewers in Ask Cush Anything (#ACA). This, and nearly a dozen news items and reports, are discussed in this week's podcast.
https://t.co/Xb81eWEZ1q https://t.co/bJqkEyx2Mg
Links:
Dr. John Cush RheumNow ( View Tweet)
